390 reports of this reaction
2.3% of all ROCURONIUM BROMIDE reports
#7 most reported adverse reaction
BRADYCARDIA is the #7 most commonly reported adverse reaction for ROCURONIUM BROMIDE, manufactured by Fresenius Kabi USA, LLC. There are 390 FDA adverse event reports linking ROCURONIUM BROMIDE to BRADYCARDIA. This represents approximately 2.3% of all 16,854 adverse event reports for this drug.
Patients taking ROCURONIUM BROMIDE who experience bradycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRADYCARDIA is a less commonly reported adverse event for ROCURONIUM BROMIDE, but still significant enough to appear in the safety profile.
In addition to bradycardia, the following adverse reactions have been reported for ROCURONIUM BROMIDE:
The following drugs have also been linked to bradycardia in FDA adverse event reports:
BRADYCARDIA has been reported as an adverse event in 390 FDA reports for ROCURONIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRADYCARDIA accounts for approximately 2.3% of all adverse event reports for ROCURONIUM BROMIDE, making it a notable side effect.
If you experience bradycardia while taking ROCURONIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.